These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care. Stargardt T; Weinbrenner S; Busse R; Juckel G; Gericke CA J Ment Health Policy Econ; 2008 Jun; 11(2):89-97. PubMed ID: 18509216 [TBL] [Abstract][Full Text] [Related]
3. Schizophrenia drug says goodbye to dopamine. Weinberger DR Nat Med; 2007 Sep; 13(9):1018-9. PubMed ID: 17828217 [No Abstract] [Full Text] [Related]
4. Do we need another atypical antipsychotic? Kasper S Eur Neuropsychopharmacol; 2008 Aug; 18 Suppl 3():S146-52. PubMed ID: 18511242 [TBL] [Abstract][Full Text] [Related]
5. Second-generation antipsychotics for schizophrenia: can we resolve the conflict? Leucht S; Kissling W; Davis JM Psychol Med; 2009 Oct; 39(10):1591-602. PubMed ID: 19335931 [TBL] [Abstract][Full Text] [Related]
7. [Expensive but nevertheless cost effect? Pharmacoeconomics of atypical neuroleptics]. Laux G; Günther W Pharm Unserer Zeit; 2002; 31(6):572-6. PubMed ID: 12481515 [No Abstract] [Full Text] [Related]
8. [Study on clozapine treatment at the Charles Perrens Hospital in Bordeaux, 15 years after its marketing]. Mercier C; Bret P; Bret MC; Queuille E Encephale; 2009 Sep; 35(4):321-9. PubMed ID: 19748368 [TBL] [Abstract][Full Text] [Related]
9. Positive allosteric modulators of the metabotropic glutamate receptor 2 for the treatment of schizophrenia. Fraley ME Expert Opin Ther Pat; 2009 Sep; 19(9):1259-75. PubMed ID: 19552508 [TBL] [Abstract][Full Text] [Related]
10. Comparison of schizophrenia drugs often favors firm funding study. Vendantam S Washington Post; 2006 Apr; ():A1, A6. PubMed ID: 16856276 [No Abstract] [Full Text] [Related]
11. Atypical antipsychotics and diabetic propensity: more questions than answers? Dinan TG; Kohen D Hum Psychopharmacol; 2003 Dec; 18(8):591-3. PubMed ID: 14696017 [No Abstract] [Full Text] [Related]
12. [Discovery of novel antipsychotics targeting group II metabotropic glutamate receptor]. Hiyoshi T; Chaki S; Okuyama S Nihon Yakurigaku Zasshi; 2012 Sep; 140(3):111-5. PubMed ID: 22975824 [No Abstract] [Full Text] [Related]
13. Use of long-acting risperidone in psychiatric disorders: focus on efficacy, safety and cost-effectiveness. Keith S Expert Rev Neurother; 2009 Jan; 9(1):9-31. PubMed ID: 19102665 [TBL] [Abstract][Full Text] [Related]
14. Importance of open access to atypical antipsychotics for the treatment of schizophrenia and bipolar disorder: a European perspective. Altamura AC; Armadoros D; Jaeger M; Kernish R; Locklear J; Volz HP Curr Med Res Opin; 2008 Aug; 24(8):2271-82. PubMed ID: 18588748 [TBL] [Abstract][Full Text] [Related]
15. [Important to atypical antipsychotics: pharmacokinetics, interaction potential and therapeutic drug monitoring]. Härtter S; Hiemke C Pharm Unserer Zeit; 2002; 31(6):546-57. PubMed ID: 12481512 [No Abstract] [Full Text] [Related]
16. Overview of the findings from the European SOHO study. Suarez D; Haro JM Expert Rev Neurother; 2008 Jun; 8(6):873-80. PubMed ID: 18505352 [TBL] [Abstract][Full Text] [Related]
17. Pregnancy and atypical antipsychotics. Ruzić K; Dadić-Hero E; Knez R; Medved P; Petrić D Psychiatr Danub; 2009 Sep; 21(3):368-70. PubMed ID: 19794358 [TBL] [Abstract][Full Text] [Related]
18. Introduction: evaluating the evidence: Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and beyond. Nasrallah HA J Clin Psychiatry; 2007; 68 Suppl 1():3-4. PubMed ID: 17286521 [No Abstract] [Full Text] [Related]
20. Recommendations from treatment guidelines for schizophrenia regarding monitoring of side effects of antipsychotics: brief review. Kozumplik O; Uzun S Psychiatr Danub; 2009 Mar; 21(1):95-8. PubMed ID: 19270630 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]